MedPath

Intranasal Fentanyl in Treatment of Labour Pain

Phase 4
Completed
Conditions
Labor Pain
Interventions
Drug: intranasal fentanyl 50 microg dose up to 250 microg
Registration Number
NCT02571179
Lead Sponsor
Kuopio University Hospital
Brief Summary

Physiological changes during pregnancy are known to affect the pharmacokinetics of many drugs. Intranasal fentanyl is an interesting option for obstetric analgesia, but its use in pregnant patients has not been established. The investigators studied pharmacokinetics of intranasal fentanyl in labouring women and to subsequently evaluate the maternal and fetal safety after administration.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
20
Inclusion Criteria
  • healthy parturients with uncomplicated, single gestation pregnancies, full term (38-42 weeks of gestation) pregnancy, agreed to participate
Exclusion Criteria
  • a disease that might affect hepatic or renal function, contraindications to opioid analgesics, fetal growth retardation, signs of fetal asphyxia by cardiotocography, meconium stained amniotic fluid or placental insufficiency. The subjects should not have received fentanyl during the previous 14 days.

Not agreed to participate

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Intranasal fentanyl 50 microg/doseintranasal fentanyl 50 microg dose up to 250 microgpatient was given intranasal fentanyl 50 microg/dose up to 250 microg
Primary Outcome Measures
NameTimeMethod
Fentanyl maximum concentrationFrom the first intranasal fentanyl dose to birth of the newborn up to 48 hours
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Kuopio University Hospital

🇫🇮

Kuopio, Northern Savo, Finland

© Copyright 2025. All Rights Reserved by MedPath